文献速递冠心病

血流储备分数指导的PCI与药物治疗稳定冠脉病变的个体患者数据荟萃分析

Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.
PubMed 文献 · Eur Heart J · 2019-01-01

该研究纳入三项随机对照试验的个体患者数据,共2400例稳定冠脉病变患者,比较FFR指导的PCI与药物治疗。中位随访35个月,FFR指导PCI组心脏死亡或心肌梗死复合终点风险显著降低(HR 0.72,95%CI 0.54-0.96;P=0.02),差异主要由心肌梗死驱动。

要点

  • FFR指导PCI较药物治疗降低心脏死亡或MI复合终点风险(HR 0.72)。
  • 获益主要由心肌梗死风险下降驱动。
  • 中位随访35个月,证据来自三项RCT的个体数据荟萃分析。

核心结论

  • 在稳定冠脉病变患者中,FFR指导的PCI较药物治疗降低心脏死亡或心肌梗死复合终点风险,差异由心肌梗死驱动。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,纳入FAME 2、DANAMI-3-PRIMULTI和Compare-Acute三项随机对照试验。
  • 共2400例受试者来自全球54个中心,1056例随机分配至FFR指导PCI组,1344例至药物治疗组。
  • FAME 2纳入稳定冠心病患者,另两项聚焦急性冠脉综合征稳定后患者的非罪犯病变。
  • 预设主要终点为心脏死亡或心肌梗死复合终点,中位随访35个月(四分位距12-60个月)。

主要发现

  • FFR指导PCI组心脏死亡或心肌梗死复合终点风险较药物治疗组降低(HR 0.72,95%CI 0.54-0.96;P=0.02)。
  • 组间差异由心肌梗死驱动。

临床怎么用

  • 对于稳定冠脉病变患者,FFR指导的PCI可作为降低心脏死亡或心肌梗死复合终点风险的策略,尤其关注心肌梗死风险下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions. METHODS AND RESULTS: We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI. CONCLUSION: In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zimmermann FM, Omerovic E, Fournier S, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019. PMID: 30596995. doi:10.1093/eurheartj/ehy812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。